Ototoxicity: A Challenge in Diagnosis and Treatment.

about

Ototoxicity: A Challenge in Diagnosis and Treatment.

Item

http://www.wikidata.org/entity/Q50300972

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Ototoxicity: A Challenge in Diagnosis and Treatment.

@en

Ototoxicity: A Challenge in Diagnosis and Treatment.

@nl

type

Item

label

Ototoxicity: A Challenge in Diagnosis and Treatment.

@en

Ototoxicity: A Challenge in Diagnosis and Treatment.

@nl

prefLabel

Ototoxicity: A Challenge in Diagnosis and Treatment.

@en

Ototoxicity: A Challenge in Diagnosis and Treatment.

@nl

P1476

Ototoxicity: A Challenge in Diagnosis and Treatment.

@en

P2093

Jason Schmiedge

http://www.w3.org/2001/XMLSchema#string

Purushothaman Ganesan

http://www.w3.org/2001/XMLSchema#string

Purushothaman Pavanjur Kothandaraman

http://www.w3.org/2001/XMLSchema#string

Simham Swapna

http://www.w3.org/2001/XMLSchema#string

Subhashini Dhandayutham

http://www.w3.org/2001/XMLSchema#string

Vinaya Manchaiah

http://www.w3.org/2001/XMLSchema#string

P2860

Medical interventions for the prevention of platinum-induced hearing loss in children with cancer

Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA)

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy

Comparison of the effectiveness of monitoring Cisplatin-induced ototoxicity with extended high-frequency pure-tone audiometry or distortion-product otoacoustic emission

Inner ear hair cell regeneration: A look from the past to the future.

Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.

Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.

Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.

Comparative adverse effect profiles of platinum drugs.

Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.

P304

59-68

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7874/JAO.2017.00360

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29471610

http://www.w3.org/2001/XMLSchema#string

P932

5894487

http://www.w3.org/2001/XMLSchema#string